He made the switch, but insurance wont cover it
#DiabetesCare #GLP1 #Orforglipron #EliLilly #ClinicalTrials #Innovation #Type2Diabetes #Pharma To view or add a comment, sign in Explore content categories
Additionally, processes involving kappa kinase (IKK-), c-Jun N-terminal kinase (JNK-1), protein kinase C (PKC), and mammalian target of rapamycin (mTOR)-driven serine modification of IRS1 also contribute to insulin resistance, further intensified by free fatty acids, lipotoxicity, oxidative stress, and inflammation (Stergios et al., 2009)
Melanoma is a disease in which malignant (cancer) cells form in melanocytes (cells that color the skin)
The FDA issued a Drug Safety Communication in 2024 stating that their review did not find clear evidence of an increased risk of suicidal thoughts or actions with GLP-1 receptor agonists, though they continue to evaluate this safety concern
Injection technique and site rotation warrant attention